HIPRA receives European Commission approval for the commercialization of its COVID-19 vaccine adapted to the LP.8.1 variant

HIPRA has received approval from the European Commission to market BIMERVAX® , its COVID-19 vaccine adapted to the LP.8.1 variant, developed and fully produced in Spain. This single-dose recombinant protein vaccine, aligned with EMA and WHO recommendations, provides protection against emerging SARS-CoV-2 variants and facilitates vaccination logistics thanks to its ready-to-use format and refrigerated storage. With this approval, HIPRA strengthens its role as a strategic player in European public health, supporting more effective and sustainable vaccination campaigns. The company combines scientific innovation, local production capacity, and a commitment to sustainability, establishing itself as a key contributor to preparedness for current and future health challenges.

The release as fetched from its publisher. hipra.com ↗